Bristol Myers Squibb Gets Expanded Opdivo Approval in U.S., Europe
By Elias Schisgall
Bristol Myers Squibb received expanded approvals for its Opdivo cancer drug to treat classical Hodgkin Lymphoma from regulators in the U.S. and the European Union.
The pharmaceutical company said Friday that the Food and Drug Administration approved Opdivo, an immunotherapy known generically as nivolumab, in combination with doxorubicin, vinblastine and dacarbazine to treat classical Hodgkin Lymphoma in patients twelve years of age or older.
The European Commission also approved Opdivo in combination with brentuximab vedotin to treat relapsed or refractory cases of the disease in patients between five and 30 years old who have already received a prior line of therapy.
"These approvals represent a defining moment for people living with classical Hodgkin Lymphoma," Monica Shaw, the Princeton, N.J., company's senior vice president of oncology commercialization, said.
The European Medicines Agency is currently evaluating a submission based on the same study that led to the FDA approval, the company said.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
March 20, 2026 17:17 ET (21:17 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
This Once-Hot AI Stock Now Looks Deeply Undervalued
5 Stocks to Buy Trading at Big Discounts
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
2 Undervalued AI Stocks With Room to Run
United States